Reviewer's report

Title: Changes in Prostaglandin E2 in patients with idiopathic OAB after BoNT-A (botulinum toxin type A) treatment: is there a clinical benefit?

Version: 3 Date: 16 August 2014

Reviewer: Antonio A Cicione

Reviewer's report:

This study assessed the blood level of PGE2 (sPGE2) in patients affected of overactive bladder syndrome (OAB) before and after Botulinum toxin type A bladder injection. Furthermore, sPGE2 level was compared to controls - healthy patients.

Briefly, the sPGE2 level was higher before than after the treatment and in the control group, indicating this prostaglandin as interesting serum marker for OAB.

Just, few considerations about this study.

The study is well displayed, carefully reporting inclusion and exclusion criteria both for medication and control group, the sPGE2 measurement method and, important, urodynamic test was also performed.

Major Compulsory Revisions

1. Please, introduce a table reporting baseline patients features both for treatment and control group.

2. Please clarify if patients received a wash out time before receiving Botulinum injection and if they underwent to other medications (also for other diseases).

3. In discussion, please report study limits as you did in abstract (small sample).

Discretionary Revisions

1. Please, consider to use a table in order to summarize the results.

2. Clarify in method how “detrusor hyperactivity and hypersensitive low capacity bladder without detrusor hyperactivity” were respectively defined.

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I declare that I have no competing interests